FOR INVESTORS

Disease outmatched by the science of degradation

FOR INVESTORS

Disease outmatched by the science of degradation

FOR INVESTORS

Disease outmatched by the science of degradation

Nurix is a biopharmaceutical company accelerating development of medicines based on targeted protein degradation, the next frontier to outmatch cancer and autoimmune diseases.

More About Nurix

View All

Minimum 15 minutes delayed. Source: LSEG

SEC Filings

January 13, 2025

Report of unscheduled material events or corporate event

8-K
View HTML
0001549595-25-000005.pdf
0001549595-25-000005.rtf
0001549595-25-000005.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

January 10, 2025

SCHEDULE 13G/A - Description

SCHEDULE 13G/A
View HTML
0001104659-25-002728.pdf
0001104659-25-002728.rtf
0001104659-25-002728.xls

January 02, 2025

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

144
View HTML
0001950047-25-000031.pdf
0001950047-25-000031.rtf
0001950047-25-000031.xls

View All

Disease outmatched by the science of degradation

Disease outmatched by the science of degradation

Disease outmatched by the science of degradation

News

Events

43rd Annual J.P. Morgan Healthcare Conference

Nurix Therapeutics ASH Annual Meeting

Piper Sandler 36th Annual Healthcare Conference

SEC Filings

Inside The Science

Advancing Our Pipeline

Learn About Us

Work at Nurix

For Investors

For Patients